Patent Application Titled "Selected Compounds For Targeted Degradation Of Brd9" Published Online (USPTO 20240245677).

C4 Therapeutics Inc. has published a patent application for a compound called Compound 1, which selectively degrades the protein BRD9 involved in cancer proliferation. Compound 1 has shown promising results in cancer cells, particularly synovial sarcoma and SMARCB1 perturbed cancer. It can be taken orally and has high selectivity for BRD9 degradation, making it a potential treatment for BRD9-mediated disorders, including certain types of cancer. The patent application also discusses the synthesis of Compound 1 and the discovery of a stable morphic form (Form N) with improved properties. Various methods for using Compound 1 or its morphic forms, alone or in combination with other therapies, are described for the treatment of BRD9-mediated disorders. [Extracted from the article]